4//SEC Filing
Kennedy Paul F. 4
Accession 0001144204-10-047804
CIK 0001095858other
Filed
Aug 31, 8:00 PM ET
Accepted
Sep 1, 5:02 PM ET
Size
15.2 KB
Accession
0001144204-10-047804
Insider Transaction Report
Form 4
Debregeas & Associes Pharma SAS
10% Owner
Transactions
- Sale
Common Stock, $0.01 par value
2010-09-01$0.75/sh−2,850,000$2,137,500→ 0 total - Sale
Common Stock, $0.01 par value
2010-09-01$0.75/sh−26,313$19,735→ 0 total - Sale
Common Stock, $0.01 par value
2010-09-01$0.75/sh−2,800,000$2,100,000→ 0 total - Sale
Common Stock, $0.01 par value
2010-09-01$0.75/sh−14,350,000$10,762,500→ 0 total
Kennedy Paul F.
Director10% Owner
Transactions
- Sale
Common Stock, $0.01 par value
2010-09-01$0.75/sh−2,850,000$2,137,500→ 0 total - Sale
Common Stock, $0.01 par value
2010-09-01$0.75/sh−14,350,000$10,762,500→ 0 total - Sale
Common Stock, $0.01 par value
2010-09-01$0.75/sh−2,800,000$2,100,000→ 0 total - Sale
Common Stock, $0.01 par value
2010-09-01$0.75/sh−26,313$19,735→ 0 total
Debregeas Patrice
Director10% Owner
Transactions
- Sale
Common Stock, $0.01 par value
2010-09-01$0.75/sh−14,350,000$10,762,500→ 0 total - Sale
Common Stock, $0.01 par value
2010-09-01$0.75/sh−26,313$19,735→ 0 total - Sale
Common Stock, $0.01 par value
2010-09-01$0.75/sh−2,800,000$2,100,000→ 0 total - Sale
Common Stock, $0.01 par value
2010-09-01$0.75/sh−2,850,000$2,137,500→ 0 total
Umbria LLC
10% Owner
Transactions
- Sale
Common Stock, $0.01 par value
2010-09-01$0.75/sh−2,850,000$2,137,500→ 0 total - Sale
Common Stock, $0.01 par value
2010-09-01$0.75/sh−26,313$19,735→ 0 total - Sale
Common Stock, $0.01 par value
2010-09-01$0.75/sh−14,350,000$10,762,500→ 0 total - Sale
Common Stock, $0.01 par value
2010-09-01$0.75/sh−2,800,000$2,100,000→ 0 total
Footnotes (6)
- [F1]On September 1, 2010, a group comprised of Debregeas & Associes Pharma SAS, Patrice R. Debregeas, Umbria LLC and Paul F. Kennedy sold to ERBA Diagnostics Mannheim GmbH (the "Purchaser"), in a privately negotiated transaction, an aggregate of 20,026,313 shares of the issuer's common stock at a purchase price of $0.75 per share (the "Transaction").
- [F2]Represents shares of the issuer's common stock sold in the Transaction which were directly owned solely by Debregeas & Associes Pharma SAS and indirectly owned by Patrice R. Debregeas, who may be deemed to control Debregeas & Associes Pharma SAS.
- [F3]Represents shares of the issuer's common stock sold in the Transaction which were directly owned solely by Patrice R. Debregeas.
- [F4]Represents shares of the issuer's common stock sold in the Transaction which were directly owned solely by Umbria LLC and indirectly owned by Paul F. Kennedy, the sole equity owner of Umbria LLC.
- [F5]Represents shares of the issuer's common stock sold in the Transaction which were directly owned solely by Paul F. Kennedy.
- [F6]In connection with the consummation of the Transaction, Patrice R. Debregeas and Paul F. Kennedy resigned as directors of the issuer, effective immediately.
Documents
Issuer
IVAX DIAGNOSTICS INC
CIK 0001095858
Entity typeother
Related Parties
1- filerCIK 0001444812
Filing Metadata
- Form type
- 4
- Filed
- Aug 31, 8:00 PM ET
- Accepted
- Sep 1, 5:02 PM ET
- Size
- 15.2 KB